MYBPC3 and Arrhythmogenic right ventricular dysplasia: In addition, clinical trials with AAV carrying cardiac myosin‐binding protein C (MYBPC3) in hypertrophic cardiomyopathy (HCM), lysosome‐associated membrane protein 2b (LAMP2b) in Danon disease and plakophilin 2a (PKP2A) in arrhythmogenic right ventricular cardiomyopathy (ARVC) patients are currently ongoing (see below, Table 1).